Canaccord Genuity Group Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN)

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reiterated by Canaccord Genuity Group in a research report issued on Friday,Benzinga reports. They currently have a $48.00 price objective on the stock.

Several other equities research analysts also recently commented on the stock. Benchmark reaffirmed a “buy” rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reissued a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. D. Boral Capital reissued a “buy” rating and issued a $23.00 price target on shares of Clene in a report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Clene Trading Down 3.4%

Clene stock opened at $5.72 on Friday. The firm has a market capitalization of $62.06 million, a P/E ratio of -2.20 and a beta of 0.62. Clene has a 1 year low of $2.28 and a 1 year high of $13.50. The business has a 50-day moving average of $4.98 and a 200-day moving average of $6.71.

Clene (NASDAQ:CLNN) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14). The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.03 million. Research analysts anticipate that Clene will post -5.19 EPS for the current fiscal year.

Insider Buying and Selling

In other Clene news, major shareholder Chidozie Ugwumba sold 15,284 shares of Clene stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $4.32, for a total value of $66,026.88. Following the transaction, the insider owned 565,045 shares of the company’s stock, valued at approximately $2,440,994.40. The trade was a 2.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 293,754 shares of company stock worth $1,587,329. Company insiders own 35.30% of the company’s stock.

Institutional Investors Weigh In On Clene

Several large investors have recently made changes to their positions in CLNN. Jones Financial Companies Lllp acquired a new stake in shares of Clene during the third quarter worth $29,000. Jane Street Group LLC bought a new stake in Clene in the 2nd quarter valued at $47,000. State Street Corp boosted its stake in Clene by 138.4% in the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after purchasing an additional 17,300 shares during the period. PEAK6 LLC acquired a new position in Clene in the 4th quarter worth $294,000. Finally, Lunt Capital Management Inc. increased its holdings in Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares in the last quarter. Institutional investors own 23.28% of the company’s stock.

Key Stories Impacting Clene

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Canaccord Genuity reaffirmed a “buy” and set a $48.00 price target, a very bullish valuation gap versus the current stock price that could attract speculative buying. Canaccord Buy/Price Target
• Positive Sentiment: D. Boral Capital reiterated a “Buy” rating on CLNN, providing additional analyst support that may limit downside and encourage holders. D. Boral Capital Note
• Neutral Sentiment: HC Wainwright published quarterly EPS forecasts for 2026 (Q1: -$0.45, Q2: -$0.48, Q3: -$0.51, Q4: -$0.45). These modelled losses keep CLNN squarely in a development-stage profile; the note is informational for forward expectations but did not change a consensus outlook materially. HC Wainwright Estimates
• Negative Sentiment: Clene reported Q4 results showing an EPS loss of ($0.88), missing the consensus of ($0.74) and signalling continued cash-burn/loss generation; revenue was nominal (about $0.08M). The earnings miss is the primary near-term negative catalyst pushing the stock down today. Company Press Release

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).